Guizhou Sanli Pharmaceutical Co Ltd Net Asset Quality Index
Guizhou Sanli Pharmaceutical Co Ltd net asset quality index. Guizhou Sanli Pharmaceutical Co Ltd (603439) has a Net Asset Quality Index of 54.4% as of September 2025. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥2.85 Billion minus total liabilities of CN¥1.30 Billion yields net assets of CN¥1.55 Billion. A higher index indicates a stronger, lower-leverage balance sheet. See Guizhou Sanli Pharmaceutical Co Ltd shareholders equity for net asset value and shareholders' equity analysis.
Quality Index
Net Assets
Total Assets
Total Liabilities
Net Asset Quality Index of Guizhou Sanli Pharmaceutical Co Ltd (2013–2024)
Net asset quality index of Guizhou Sanli Pharmaceutical Co Ltd from 2013 to 2024. This chart shows how Guizhou Sanli Pharmaceutical Co Ltd's Net Asset Quality Index has evolved across 12 annual periods from 2013 to 2024. As of September 2025, the index stands at 54.4%, representing net assets of CN¥1.55 Billion against total assets of CN¥2.85 Billion CNY. Check 603439 strategic asset allocation to assess the company's strategic physical and investment asset allocation.
Guizhou Sanli Pharmaceutical Co Ltd Net Asset Quality Index by Year (2013–2024)
Guizhou Sanli Pharmaceutical Co Ltd net asset quality index by year from 2013 to 2024. The table below presents the year-by-year Net Asset Quality Index for Guizhou Sanli Pharmaceutical Co Ltd from 2013 to 2024, covering 12 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For live market cap and overall valuation, see how much is Guizhou Sanli Pharmaceutical Co Ltd worth.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 50.0% | CN¥1.59 Billion | CN¥3.19 Billion | CN¥1.60 Billion | ▼ -8.6 pp |
| 2023 | 58.5% | CN¥1.71 Billion | CN¥2.92 Billion | CN¥1.21 Billion | ▼ -9.6 pp |
| 2022 | 68.2% | CN¥1.24 Billion | CN¥1.82 Billion | CN¥578.40 Million | ▼ -5.3 pp |
| 2021 | 73.5% | CN¥1.03 Billion | CN¥1.40 Billion | CN¥372.93 Million | ▼ -4.5 pp |
| 2020 | 78.0% | CN¥981.88 Million | CN¥1.26 Billion | CN¥276.91 Million | ▼ -11.1 pp |
| 2019 | 89.1% | CN¥651.09 Million | CN¥730.81 Million | CN¥79.72 Million | ▼ -0.7 pp |
| 2018 | 89.8% | CN¥518.02 Million | CN¥576.70 Million | CN¥58.69 Million | ▲ +6.1 pp |
| 2017 | 83.7% | CN¥473.36 Million | CN¥565.43 Million | CN¥92.07 Million | ▲ +0.6 pp |
| 2016 | 83.1% | CN¥430.59 Million | CN¥518.02 Million | CN¥87.44 Million | ▲ +11.6 pp |
| 2015 | 71.5% | CN¥216.53 Million | CN¥302.67 Million | CN¥86.14 Million | ▲ +27.7 pp |
| 2014 | 43.8% | CN¥108.92 Million | CN¥248.58 Million | CN¥139.67 Million | ▲ +9.2 pp |
| 2013 | 34.6% | CN¥69.09 Million | CN¥199.62 Million | CN¥130.52 Million | — |